DESCRIPTION
The eyeWatch system comprises the eyeWatch Adjustable Glaucoma Drainage Device (AGDD) and the external measurement/adjustment device, hereafter called eyeWatch Pen (Fig. 1). The eyeWatch system is designed to allow physicians to regulate intraocular pressure in patients suffering from glaucoma. The eyeWatch implant contains a deformable drainage tube, which drains aqueous humor from the anterior chamber into a bleb formed under the conjunctiva. The eyeWatch shall be connected in series to a Seton tube commercially available (only the Baerveldt Glaucoma Implant or the eyePlate). It is not recommended to use the eyeWatch device as a stand-alone device. The eyeWatch encompasses a mechanism that permits adjustment of the postoperative intraocular pressure. The control of the fluidic resistance is performed noninvasively using the eyeWatch Pen or the eyeWatch Pen single use.

The eyeWatch Pen has been designed to help the physician perform two essential functions:
1. Measure the present functional position of the implant.
2. Perform a noninvasive adjustment of this functional position, in order to adjust the drainage characteristics (fluidic resistance) of the implant.

The eyeWatch implant contains a deformable drainage tube, which drains aqueous humor from the anterior chamber into a bleb formed under the conjunctiva. The eyeWatch shall be connected in series to a Seton tube commercially available (only the Baerveldt Glaucoma Implant or the eyePlate). It is not recommended to use the eyeWatch device as a stand-alone device. The eyeWatch encompasses a mechanism that permits adjustment of the postoperative intraocular pressure. The control of the fluidic resistance is performed noninvasively using the eyeWatch Pen or the eyeWatch Pen single use.

INDICATIONS FOR USE
The eyeWatch system is indicated for patients suffering from glaucoma where medical and/or conventional surgical treatments have failed. The eyeWatch system is intended to drain aqueous humor from the anterior chamber to the subconjunctival space and to regulate non-surgically the intraocular pressure during the early post-operative period.

CONTRAINDICATIONS
The implantation of the eyeWatch implant is contraindicated if one or more of the following conditions exist:
1. Diagnosis of angle-closure glaucoma, neovascular glaucoma.
2. Patient with ocular malformations such as microphthalmia.
3. Patient with corneal opacifications or irregularities that may interfere with IOP measurements.
4. History of previous corneal transplant surgery.
5. Patient with concurrent inflammatory/infective eye disorder.

WARNINGS
The implanting surgeon should be familiar with the instructions for use. The integrity of the package, the eyeWatch implant and the eyeWatch Pen single use should be examined. If the package is opened but not used, the implant should be returned to the manufacturer for exchange. The eyeWatch system, like every other ophthalmic implant and filtering device, shall be handled with care. The implant shall not be dropped-off, the forceps used to grip the device should not have sharp teeth. The implant shall not be handled in close vicinity of a source of strong magnetic field such as power units or strong permanent magnets. The implant shall not be sutured and the surgery terminated without completion of a functional test, i.e., verify that the device is adjustable (ability to change the functional position of the implant with the eyeWatch Pen single use) and that drainage (flow of aqueous humor through the device) is positively assessed when the implant is in an open position.

Figure 1: The eyeWatch system, comprising the implant (top left), its measurement/adjustment device (eyeWatch Pen office version, top right) and the single use eyeWatch Pen (bottom).

PRECAUTIONS
The eyeWatch implant and the single-use eyeWatch Pen are supplied sterile in two sealed separate bags. Both devices are sterilized by irradiation. The opening of the packaging and the handling of the devices shall obey the Good Clinical Practice in surgery. The rules to keep the implant sterile throughout the entire surgery shall be strictly followed. The eyeWatch implant should not be used if sterility is compromised. The eyeWatch implant as well as the eyeWatch Pen single use are intended for single use only. To prevent cross-contaminations and/or ineffective treatment, the eyeWatch implant and the eyeWatch Pen single use shall not be re-used and/or re-sterilized. The implants should be stored in a dry environment and at room temperature.

The eyeWatch implant contains a magnet and thus tends to stick to ferromagnetic tools. The needle used to create the comeo-scleral tunnel should have a 26G diameter. Prior to inserting the implant into the eye, care should be given to prevent possible hemorrhage (hyphema). The presence of blood into the tube of the implant could create clots, blocking the aqueous humor drainage and making the device non-functional. When necessary, a conventional space maintainer should be used instead of injecting viscoelastic in the anterior chamber to prevent such viscoelastic from entering and potentially clogging the device.

MRI
Tests have demonstrated that the MRI (<3 T) of the head of the patient is permitted, however not recommended, within the first two weeks post implantation. If the patient has to undergo an MRI at any time, it is highly recommended that the patient get the eyeWatch implant magnet position controlled at the clinic where the surgery was performed.

KNOWNS COMPLICATIONS / ADVERSE REACTIONS
The main known complications or adverse reactions are associated with the filtering surgery and might comprise (not an exhaustive list): prolonged IOP control troubles in the form of IOP spikes; flat or shallow chamber; ocular hypotony; leaks at the level of the filtering bleb; inflammation and/or infection of the filtering bleb (blebitis); filtering bleb fibrosis and encystment; increased risks of developing cataract; iritis associated with anterior uveitis; enhanced and accelerated fibrosis of the filtering bleb; extrusion of the implant; exposure of the drainage tube; ocular movement limitation in lateral or upper/lower gaze; eye irritation; hyphema; choroidal or retinal detachment; endophthalmitis; tube erosion; tube touch to cornea; macular or corneal edema; tube block by iris; diplopia; vision alteration.

LIFETIME
The eyeWatch device can be implanted during 5 years.

USER PROFILE
The eyeWatch is intended to be used by surgeons who have experience with drainage devices in glaucoma surgery.

PATIENT INFORMATION
It is recommended that each patient receive information regarding Glaucoma implants prior to the decision to implant.

PATIENT CARD:
An ID card is supplied in the implant packaging. This card should be given to the patient with instructions to keep as a permanent record of the implant and to show the card to any eye care practitioner seen in the future.

PREOPERATIVE ACTIVITIES
PREPARATION STEPS
The preparation for the filtering surgery using the eyeWatch system does not significantly differ from that of conventional filtering surgery, with or without classical drainage tube. The anesthesia, the disinfection of the eye and the sterile draping are absolutely similar.

EQUIPMENT REQUIRED
The use of the eyeWatch system does not require any specific equipment, other than standard surgical equipment used in ophthalmic surgery.

OPERATIVE ACTIVITIES
IMPLANTATION PROCEDURE
The eyeWatch implant is placed using a surgical technique analogous to the one used for other Glaucoma drainage implant (Fig. 2). A seton tube is placed under the conjunctiva. A 26-gauge needle is inserted into the anterior chamber through the center of the “blue line” at an angle parallel to the iris plane. The nozzle for the eyeWatch implant is inserted all the way into the anterior chamber through the ostium created by the needle. The device is secured in place within the sclera by stitching in the rear of the device through the two stitch holes using a 9-0 or 10-0 nylon suture with a spatulated needle. The tube of the seton tube is then connected to the eyeWatch device. A scleral patch is then sutured in place using the same type of suture. Finally, the conjunctiva is carefully closed using appropriate suturing technique.
Step 2. Adjustment

The physician repeats Step 1 and obtains a reading of the new angular position of the implant. If unsatisfied, he can repeat Step 2 and 3 (Fig. 3, step 4).

Step 4. Validation of adjustment

The physician performs a measurement of IOP using a tonometer or similar device. This can be done only after IOP has reached the new steady state (time estimated in the order of 15 – 30 minutes). If IOP is now within the physiological or desired range, the procedure is complete. Otherwise further adjustment is required.

CONTROL PROCEDURE

After proper positioning of the device into the eye, the surgeon should perform a functional test using the eyeWatch Pen single use the following way:

1. Check the actual position of the magnetic disk
2. Adjust the implant drainage opening using the eyeWatch Pen single use toward the fully open position
3. Verify with the eyeWatch Pen single use that the implant drainage opening is indeed set at the fully open position
4. Visually check the patency of the device, seen by aqueous humor dropping from the distal end of the silicon tube
5. Adjust the implant drainage opening using the eyeWatch Pen toward the functional position of the implant before adjustment. The adjustment procedure includes the following three sequential phases:
   a. Fornix based incision of the conjunctiva. Careful dissection of the paracenthesis and injection of local anaesthesia (e.g. retrobulbar or peribulbar anaesthesia)
   b. In case of clinical emergency where the surgeon considers that the implant needs to be explanted, the procedure should include the following steps:
      i. Use the eyeWatch Pen to remove the implant drainage system from the eye. The device is delivered sterile to the operator, who performs a measurement of IOP before and after the adjustment, using appropriate means (i.e., tonometry) and, if necessary, repeats the adjustment until the desired IOP is achieved.
   c. If not, it is recommended to send the non-functional eyeWatch Pen back to Rheon Medical for inspection.

ACCESSORIES

The eyeWatch implant and the eyeWatch Pen single use are delivered sterile inside a double Tyvek® pouch, guaranteeing sterility and integrity during storage and transport. Although the devices are designed to sustain significant contact forces, it is recommended to handle it gently using standard blunt surgical equipment (forceps). No special delivery system is required for the surgical placement of the eyeWatch implant.

APPLICATION OF MEDICATION DURING OPERATION

No specific medication needs to be used or applied during the surgery using the eyeWatch system.

EXPLANATION

In case of clinical emergency where the surgeon considers that the implant should be explanted, the procedure should include the following steps:

1. Local anaesthesia (e.g. retrobulbar or peribulbar anaesthesia).
2. Preparation of a paracenthesis and injection of viscoelastics to maintain the anterior chamber.
3. Gentle grasp the eyeWatch onto the sclera. No special delivery system is required for the surgical placement of the eyeWatch implant.
4. Attachment of the eyeWatch Pen single use to the eyeWatch implant. No special delivery system is required for the surgical placement of the eyeWatch implant.

POST-OPERATIVE ACTIVITIES

USE OF THE EYEWATCH PEN TO ADJUST THE IOP

The adjustment of the fluidic resistance of the eyeWatch implant is performed using the external adjustment device (eyeWatch Pen). The eyeWatch Pen (not disposable version) for post-operative adjustments is not delivered sterile because it is not intended to be in contact with exposed body tissues or fluids. The adjustment is performed using the following three sequential phases:

Step 1: Control of the functional position of the implant before adjustment. The physician who wishes to perform an adjustment (increase or decrease) of the hydraulic resistance of the implant needs first to determine the current angular position of the eyeWatch system. The physician asks the patient to remain still and with the head in a vertical position. The physician then puts on the eyelead, exposes the sclera and places the compass flat at 1 to 2 mm from the eye, right above the eyeWatch implant (see schematic in Fig. 3). The magnetic needle is colored to indicate the “north pole” and the transparent cover slip or the outer rim of the compass housing contains graduations for easier reading of the angular position of the needle. The physician can thus read the angular position indicated by the compass (Fig. 3, step 1).

Step 2: Adjustment. Once the angular position is read, the operator flips the eyeWatch Pen 180 degrees to bring the eyeWatch Pen’s magnet above the implant and magnetically couple the external magnet to the internal magnetic disk. The operator then pivots the eyeWatch Pen around the implant to any direction wished, thus forcing the internal magnetic disk to rotate accordingly (Fig. 3, step 2 & 3).

Step 3: Verification. The physician repeats Step 1 and obtains a reading of the new angular position of the implant. If unsatisfied, he can repeat Step 2 and 3 (Fig. 3, step 4).

Step 4: Validation of adjustment. The physician performs a measurement of IOP using a tonometer or similar device. This can be done only after IOP has reached the new steady state (time estimated in the order of 15 – 30 minutes). If IOP is now within the physiological or desired range, the procedure is complete. Otherwise further adjustment is required.